Minimizing the immunogenicity of protein therapeutics
- 1 January 2004
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 9 (2) , 82-90
- https://doi.org/10.1016/s1359-6446(03)02953-2
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasiaCurrent Medical Research and Opinion, 2003
- Computational stabilization of human growth hormoneProtein Science, 2002
- Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screeningProtein Science, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- PegylationClinical Pharmacokinetics, 2001
- Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigenKidney International, 1998
- Infectious Diseases and Immunity: Special Reference to Major Histocompatibility ComplexEmerging Infectious Diseases, 1997
- In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic microspheres does not require adjuvantInternational Immunology, 1995
- The Role of the Major Histocompatibility Complex in AutoimmunityClinical Immunology and Immunopathology, 1993
- Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys*1Fundamental and Applied Toxicology, 1991